BD4BO-DO>ITis a two-year project funded by the European Commission's Innovative Medicines Initiative (IMI) 2 programme launched to facilitate the transition towards outcomes-focused healthcare systems across Europe. The Coordination and Support Action will run from February 2017 to February 2019.
Over the next two years, the Big Data for Better Outcomes, Policy Innovation, and Healthcare Systems Transformation (BD4BO-DO>IT) consortium will coordinate the IMI 2 Big Data for Better Outcomes (BD4BO) programme, identifying and addressing opportunities for data-driven healthcare system transformation based on input from healthcare systems stakeholders and on knowledge, data and tools developed in the BD4BO disease specific projects: Alzheimer’s Disease, hematologic malignancies, cardiovascular diseases and prostate cancer.
To fully exploit the transformative potential of big data in healthcare, the detailed personal and biological information available in existing databases need to be considered across the spectrum of care delivery, starting from the development of innovative medicines and treatments to market access, adoption and use in healthcare systems by providers and patients. The BD4BO programme was launched with the objective of harnessing the opportunities of big data to promote patient-centred outcomes-focused healthcare in Europe and to develop innovative methods for integrating, analysing, and using big data.
BD4BO-DO>IT will act as a coordination platform (Coordination and Support Action) for the programme, realising synergies across disease specific projects and maximising impact on European healthcare systems. The project will in particular: aggregate learnings and disseminate findings from the BD4BO projects on methods of selecting and measuring outcomes in real world settings, develop minimum data privacy standards for the collection, use, storage and transfer of clinical and biological data, engage with key stakeholders to understand value and limitations of outcomes based approaches, and recommend areas for future collaborative research to address gaps in standards, methodologies and tools, among others.
The European Cancer patient Coalition will collaborate with European expert patient groups in order to develop further the ICFs and their supporting materials. Patient organisations and other stakeholders will generate an iterative, consultative process to develop successive versions of minimum data privacy standards and structure recommendations for these ICFs.
ECPC will participate in compiling concise and comprehensive documents which will provide European patients with the basic knowledge to understand the importance and power of clinical trials, bio banking, and exploratory research such as biomarkers. ECPC will also contribute to the successful dissemination of the project's deliverables.
Public Private Partnership
London School of Economics and Political Science and Novartis lead the "Big Data for Better Outcomes, Policy Innovation, and Healthcare Systems Transformation (BD4BO-DO>IT)" under the Innovative Medicines Initiative 2 Joint Undertaking. IMI is a partnership between the European Union’s Horizon 2020 programme and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).
ECPC: Isabelle Manneh-Vangramberen, European Cancer Patient Coalition's Projects Coordinator
BD4BO-DO>IT is funded by the Innovative Medicines Initiative (IMI): a part of the EU Horizon 2020 Programme, Grant Agreement N° 116055.
Big Data for Better Outcomes Annual Meeting
BD4BO Coordination and Support Action Launched
Press Release: New public-private partnership launched
Big Data for Better Outcomes paper in EuroHealth